teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 48

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Browse source 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents 2026-03-16 14:12:58 +00:00
parent e881bbef74
commit a4da9a17c4
2 changed files with 25 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
### Additional Evidence (challenge)
*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even oral Wegovy launched at $149-$299/month (January 2026), 50-75% below injectable pricing. If international generics reach $40-$100/month by 2028-2030 (as this trajectory suggests), the inflection point where price compression overtakes volume growth moves significantly earlier than 2035. The 'inflationary through 2035' claim depends on sustained high pricing, but international arbitrage pressure and generic competition create a much steeper price decline curve than assumed.
---
Relevant Notes:

20
inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md
View file

@ -7,9 +7,13 @@ date: 2026-02-01
domain: health
secondary_domains: [internet-finance]
format: article
status: unprocessed
status: enrichment
priority: medium
tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -50,3 +54,17 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
## Key Facts
- Semaglutide US patents extend to 2031-2032
- Semaglutide Europe patents extend to 2031-2032
- Canada semaglutide patents expired January 4, 2026
- Brazil generic semaglutide competition opens March 2026
- India semaglutide patents expire March 2026
- China has 17+ generic semaglutide candidates in Phase 3 trials
- Oral Wegovy launched January 2026 at $149-$299/month
- Medicare negotiated price for GLP-1: $245/month
- Projected China/India generic pricing: $40-$50/month
- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry
- Biomm + Biocon (India) preparing generic semaglutide for Brazil market